Markers of response for the antiangiogenic agent bevacizumab
D Lambrechts, HJ Lenz, S de Haas… - Journal of Clinical …, 2013 - ascopubs.org
Bevacizumab is the first antiangiogenic therapy proven to slow metastatic disease
progression in patients with cancer. Although it has changed clinical practice, some patients …
progression in patients with cancer. Although it has changed clinical practice, some patients …
Anti-VEGF therapies in the clinic
KL Meadows, HI Hurwitz - Cold Spring …, 2012 - perspectivesinmedicine.cshlp.org
The development and use of antiangiogenesis agents, particularly those targeting vascular
endothelial growth factor (VEGF), has become an integral component of anticancer …
endothelial growth factor (VEGF), has become an integral component of anticancer …
[HTML][HTML] ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making
HJ Schmoll, E Van Cutsem, A Stein, V Valentini… - Annals of oncology, 2012 - Elsevier
Colorectal cancer (CRC) is the most common tumour type in both sexes combined in
Western countries. Although screening programmes including the implementation of faecal …
Western countries. Although screening programmes including the implementation of faecal …
Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial
E Van Cutsem, S de Haas, YK Kang, A Ohtsu… - Journal of clinical …, 2012 - ascopubs.org
Purpose The AVAGAST study showed that adding bevacizumab to chemotherapy in patients
with advanced gastric cancer improves progression-free survival and tumor response rate …
with advanced gastric cancer improves progression-free survival and tumor response rate …
Bevacizumab: a review of its use in advanced cancer
GM Keating - Drugs, 2014 - Springer
The humanized monoclonal antibody bevacizumab (Avastin®) has been available in the EU
since 2005. Results of phase III trials demonstrate that adding intravenous bevacizumab to …
since 2005. Results of phase III trials demonstrate that adding intravenous bevacizumab to …
Targeted inhibition of VEGF receptor 2: an update on ramucirumab
JM Clarke, HI Hurwitz - Expert opinion on biological therapy, 2013 - Taylor & Francis
Introduction: Ramucirumab (IMC-1121B) is a fully humanized IgG1 monoclonal antibody,
targeting the extracellular domain of VEGF receptor 2 (VEGFR2). Numerous Phase I–II trials …
targeting the extracellular domain of VEGF receptor 2 (VEGFR2). Numerous Phase I–II trials …
The association of alternate VEGF ligands with resistance to anti-VEGF therapy in metastatic colorectal cancer
Background Circulating angiogenic factors are altered in patients with mCRC receiving
bevacizumab. Evaluation of alterations in levels of VEGF ligands may provide insights into …
bevacizumab. Evaluation of alterations in levels of VEGF ligands may provide insights into …
ROS1 and ALK Fusions in Colorectal Cancer, with Evidence of Intratumoral Heterogeneity for Molecular Drivers
DL Aisner, TT Nguyen, DD Paskulin, AT Le… - Molecular Cancer …, 2014 - AACR
Activated anaplastic lymphoma kinase (ALK) and ROS1 tyrosine kinases, through gene
fusions, have been found in lung adenocarcinomas and are highly sensitive to selective …
fusions, have been found in lung adenocarcinomas and are highly sensitive to selective …
Treatment decisions after diagnosis of metastatic colorectal cancer
TH Cartwright - Clinical colorectal cancer, 2012 - Elsevier
Treatment of metastatic colorectal cancer (mCRC) involves the use of active cytotoxic drugs
(irinotecan, oxaliplatin, 5-fluorouracil [5-FU], and capecitabine) and biological agents …
(irinotecan, oxaliplatin, 5-fluorouracil [5-FU], and capecitabine) and biological agents …
[HTML][HTML] Understanding and targeting resistance to anti-angiogenic therapies
JM Clarke, HI Hurwitz - Journal of gastrointestinal oncology, 2013 - ncbi.nlm.nih.gov
Therapies targeting tumor angiogenesis are used in a variety of malignancies, however not
all patients benefit from treatment and impact on tumor control may be transient and modest …
all patients benefit from treatment and impact on tumor control may be transient and modest …